Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 56.16
NVAX's Cash to Debt is ranked higher than
73% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. NVAX: 56.16 )
NVAX' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 56.16

Equity to Asset 0.87
NVAX's Equity to Asset is ranked higher than
89% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVAX: 0.87 )
NVAX' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.98
Current: 0.87

0.14
0.98
F-Score: 4
Z-Score: 19.54
M-Score: -1.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -250.70
NVAX's Operating margin (%) is ranked higher than
63% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. NVAX: -250.70 )
NVAX' s 10-Year Operating margin (%) Range
Min: -11502.46   Max: -38.46
Current: -250.7

-11502.46
-38.46
Net-margin (%) -248.54
NVAX's Net-margin (%) is ranked higher than
63% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NVAX: -248.54 )
NVAX' s 10-Year Net-margin (%) Range
Min: -12414.15   Max: -40.49
Current: -248.54

-12414.15
-40.49
ROE (%) -25.58
NVAX's ROE (%) is ranked higher than
70% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. NVAX: -25.58 )
NVAX' s 10-Year ROE (%) Range
Min: -281.15   Max: -22.5
Current: -25.58

-281.15
-22.5
ROA (%) -22.03
NVAX's ROA (%) is ranked higher than
70% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. NVAX: -22.03 )
NVAX' s 10-Year ROA (%) Range
Min: -126.32   Max: -13.24
Current: -22.03

-126.32
-13.24
ROC (Joel Greenblatt) (%) -367.93
NVAX's ROC (Joel Greenblatt) (%) is ranked higher than
70% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. NVAX: -367.93 )
NVAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -661.24   Max: -32.49
Current: -367.93

-661.24
-32.49
EBITDA Growth (%) -4.20
NVAX's EBITDA Growth (%) is ranked higher than
79% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NVAX: -4.20 )
NVAX' s 10-Year EBITDA Growth (%) Range
Min: -58.5   Max: 101.4
Current: -4.2

-58.5
101.4
EPS Growth (%) -3.00
NVAX's EPS Growth (%) is ranked higher than
81% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NVAX: -3.00 )
NVAX' s 10-Year EPS Growth (%) Range
Min: -45.6   Max: 52.3
Current: -3

-45.6
52.3
» NVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2012

NVAX Guru Trades in Q2 2012

Jim Simons Sold Out
» More
Q3 2013

NVAX Guru Trades in Q3 2013

Jean-Marie Eveillard 800,000 sh (New)
George Soros 573,000 sh (New)
Steven Cohen 13,400 sh (New)
» More
Q4 2013

NVAX Guru Trades in Q4 2013

David Swensen 25,398 sh (New)
Paul Tudor Jones 26,930 sh (New)
Jean-Marie Eveillard 800,000 sh (unchged)
Steven Cohen Sold Out
George Soros Sold Out
» More
Q1 2014

NVAX Guru Trades in Q1 2014

Steven Cohen 192,191 sh (New)
Paul Tudor Jones 29,939 sh (+11.17%)
David Swensen Sold Out
Jean-Marie Eveillard 200,000 sh (-75%)
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Reduce -75%0.01%$4.13 - $6.65 $ 4.4-21%200000
George Soros 2013-12-31 Sold Out 0.02%$2.76 - $5.16 $ 4.425%0
George Soros 2013-09-30 New Buy0.02%$2.25 - $3.39 $ 4.456%573000
Jean-Marie Eveillard 2013-09-30 New Buy0.01%$2.25 - $3.39 $ 4.456%800000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.70
NVAX's P/B is ranked higher than
75% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. NVAX: 4.70 )
NVAX' s 10-Year P/B Range
Min: 0.74   Max: 17.91
Current: 4.7

0.74
17.91
P/S 32.80
NVAX's P/S is ranked higher than
67% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. NVAX: 32.80 )
NVAX' s 10-Year P/S Range
Min: 5.93   Max: 409
Current: 32.8

5.93
409
EV-to-EBIT -16.48
NVAX's EV-to-EBIT is ranked higher than
55% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVAX: -16.48 )
NVAX' s 10-Year EV-to-EBIT Range
Min: 24.5   Max: 36.7
Current: -16.48

24.5
36.7
Current Ratio 9.40
NVAX's Current Ratio is ranked higher than
88% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NVAX: 9.40 )
NVAX' s 10-Year Current Ratio Range
Min: 0.44   Max: 37
Current: 9.4

0.44
37
Quick Ratio 9.40
NVAX's Quick Ratio is ranked higher than
89% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. NVAX: 9.40 )
NVAX' s 10-Year Quick Ratio Range
Min: 0.44   Max: 37
Current: 9.4

0.44
37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.73
NVAX's Price/Net Cash is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. NVAX: 10.73 )
NVAX' s 10-Year Price/Net Cash Range
Min: 2.48   Max: 193.8
Current: 10.73

2.48
193.8
Price/Net Current Asset Value 9.78
NVAX's Price/Net Current Asset Value is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. NVAX: 9.78 )
NVAX' s 10-Year Price/Net Current Asset Value Range
Min: 3.98   Max: 418.8
Current: 9.78

3.98
418.8
Price/Tangible Book 7.86
NVAX's Price/Tangible Book is ranked higher than
72% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. NVAX: 7.86 )
NVAX' s 10-Year Price/Tangible Book Range
Min: 3.01   Max: 187.5
Current: 7.86

3.01
187.5
Price/Median PS Value 0.82
NVAX's Price/Median PS Value is ranked higher than
89% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NVAX: 0.82 )
NVAX' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 7.63
Current: 0.82

0.1
7.63
Forward Rate of Return (Yacktman) -20.83
NVAX's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. NVAX: -20.83 )
NVAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.5   Max: -17.2
Current: -20.83

-24.5
-17.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NVV.Germany
Novavax, Inc. was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical Company focused on creating differentiated, value- upon current preventive options for a range of infectious diseases. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ('VLPs') and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the major structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus ('RSV'). Its product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus (RSV). Further, CPL Biologics Private Limited (the JV), its joint venture Company in India, is actively developing a rabies vaccine candidate that was genetically engineered by Novavax. The JV recently completed initial pre-clinical immunogenicity studies on this new vaccine candidate and is progressing with pre-clinical toxicology studies. The Company's main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc. It is also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.
» More Articles for NVAX

Headlines

Articles On GuruFocus.com
comment on NVAX Mar 16 2013 
comment on NVAX Mar 16 2013 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
creiter note on NVAX Jan 03 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Reports Second Quarter 2009 Financial Results Aug 07 2009 
Novavax Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
Trade-Ideas: Novavax (NVAX) Is Today's "Perilous Reversal" Stock Jul 10 2014
Novavax Recognized as One of The Washington Post's Top Workplaces Jun 23 2014
Novavax Announces Management Promotions Jun 19 2014
Long-Time Novavax Board Member Jack Marsh Assumes Role of Director Emeritus Jun 18 2014
Long-Time Novavax Board Member Jack Marsh Assumes Role of Director Emeritus Jun 18 2014
NOVAVAX INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 18 2014
Insider Trading Alert - UBSI, NVAX And RSG Traded By Insiders Jun 18 2014
NOVAVAX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 11 2014
Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering Jun 11 2014
NOVAVAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Jun 09 2014
Novavax (NVAX) Is Today's Dead Cat Bounce Stock Jun 09 2014
Novavax (NVAX) Crumbles: Stock Tumbles by 7.7% Jun 09 2014
US STOCKS-Jobs report takes Dow, S&P to fresh record highs Jun 06 2014
US STOCKS-Jobs report lifts market, volatility index at lowest since '07 Jun 06 2014
US STOCKS-Cyclicals lift Wall St to records after jobs report Jun 06 2014
US STOCKS-Wall St up as cyclical stocks gain after jobs report Jun 06 2014
Why Novavax (NVAX) Stock Is Down Today Jun 06 2014
US STOCKS-Futures point to higher Wall St open after jobs report Jun 06 2014
US STOCKS-Futures point to higher Wall St open after jobs report Jun 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide